Subscribe To

Price Alert Latest News Economic Calendar News

TECH / Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q4 2022 Results - Earnings Call Transcript

Bio-Techne Corporation (NASDAQ:TECH ) Q4 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Corporate Participants David Clair - Vice President, Investor Relations and Corporate Development Chuck Kummeth - Chief Executive Officer Jim Hippel - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Jacob Johnson - Stephens Dan Arias - Stifel Catherine Schulte - Baird Alex Nowak - Craig-Hallum Patrick Donnelly - Citi Paul Knight - KeyBanc Operator Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Fourth Quarter of Fiscal Year 2022. At this time, all participants have been placed in a listen-only mode and the call will be opened for questions following management's prepared remarks. Read More

Demo Live Account See Partner Details

Content Topics

Bio

Techne

Corporation

TECH

Chuck

Kummeth

2022

Results

Bio techne

tech

Earnings

Transcript

Stock

Posted: Aug 6 2022, 23:59

Author Name: Seeking Alpha

TECH News

By Zacks Investment Research
October 31, 2023

Techne (TECH) Q1 Earnings and Revenues Miss Estimates

Techne (TECH) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to earnings

By Zacks Investment Research
August 8, 2023

Techne (TECH) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Techne (TECH) give a sense of how its business performed in the quarter ended June 2023, it might be worth considerin

By Zacks Investment Research
August 8, 2023

Techne (TECH) Meets Q4 Earnings Estimates

Techne (TECH) came out with quarterly earnings of $0.55 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.51 per s

By Zacks Investment Research
June 1, 2023

PBYI or TECH: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Techne (TECH). But which o

By Seeking Alpha
May 18, 2023

Bio-Techne Corporation: Long-Term Quality, But At A Price

Bio-Techne Corporation has been a long term value creator, combining organic growth with sound M&A deals. This has resulted in long-term value creatio

By Zacks Investment Research
May 16, 2023

PBYI vs. TECH: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Puma Biotech (PBYI) or Techne (TECH). But w

By Seeking Alpha
May 3, 2023

Bio-Techne Corporation (TECH) Q3 2023 Earnings Call Transcript

Bio-Techne Corporation (NASDAQ:TECH ) Q3 2023 Earnings Conference Call May 3, 2023 9:00 AM ET Company Participants David Clair – Vice President-Inve

By Zacks Investment Research
May 3, 2023

Techne (TECH) Meets Q3 Earnings Estimates

Techne (TECH) came out with quarterly earnings of $0.53 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.54 per s

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.